L. Mariani et al., POSTMENOPAUSAL ENDOMETRIAL HYPERPLASIA - ROLE OF DANAZOL THERAPY, International journal of gynaecology and obstetrics, 44(2), 1994, pp. 155-159
OBJECTIVES: To confirm the effectiveness of danazol in the management
of simple or complex endometrial hyperplasia without atypical features
, as has been demonstrated previously. METHODS: Seventy-six patients a
ffected by postmenopausal histologically-confirmed endometrial hyperpl
asia with uterine bleeding were submitted to danazol therapy at a dose
of 400 mg/day for 3 consecutive months. RESULTS: After cessation of t
reatment, 82.8% of the patients (63/76 enrolled) showed a conversion o
f the hyperplasia into atrophic (65.8%) secretory (11.9%) or prolifera
tive (4.2%) endometrium at the histological examination. Uterine bleed
ing disappeared, during the therapy, in 90% of the responders (59/63).
CONCLUSIONS: Although 17.1% of the women had a persistence of the hyp
erplasia and 8.4% of the symptom-free women relapsed after 4 months of
follow-up, this experience confirms the effectiveness of danazol ther
apy in hyperplastic endometrial lesions. Nevertheless, a study compari
ng danazol and progestin therapy is required.